We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.41%. Elsewhere, the Dow gained 0.98%, while the tech-heavy Nasdaq added 0.02%.
Heading into today, shares of the company had lost 5.23% over the past month, lagging the Medical sector's loss of 0.78% and the S&P 500's gain of 4.68% in that time.
Wall Street will be looking for positivity from Biogen Inc. as it approaches its next earnings report date. In that report, analysts expect Biogen Inc. to post earnings of $4.19 per share. This would mark a year-over-year decline of 12.16%. Our most recent consensus estimate is calling for quarterly revenue of $2.47 billion, down 11.13% from the year-ago period.
BIIB's full-year Zacks Consensus Estimates are calling for earnings of $16.36 per share and revenue of $9.99 billion. These results would represent year-over-year changes of -14.88% and -9.08%, respectively.
It is also important to note the recent changes to analyst estimates for Biogen Inc.These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Biogen Inc. currently has a Zacks Rank of #3 (Hold).
Investors should also note Biogen Inc.'s current valuation metrics, including its Forward P/E ratio of 12.33. For comparison, its industry has an average Forward P/E of 21, which means Biogen Inc. is trading at a discount to the group.
We can also see that BIIB currently has a PEG ratio of 0.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.41 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
Biogen Inc. (BIIB - Free Report) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.41%. Elsewhere, the Dow gained 0.98%, while the tech-heavy Nasdaq added 0.02%.
Heading into today, shares of the company had lost 5.23% over the past month, lagging the Medical sector's loss of 0.78% and the S&P 500's gain of 4.68% in that time.
Wall Street will be looking for positivity from Biogen Inc. as it approaches its next earnings report date. In that report, analysts expect Biogen Inc. to post earnings of $4.19 per share. This would mark a year-over-year decline of 12.16%. Our most recent consensus estimate is calling for quarterly revenue of $2.47 billion, down 11.13% from the year-ago period.
BIIB's full-year Zacks Consensus Estimates are calling for earnings of $16.36 per share and revenue of $9.99 billion. These results would represent year-over-year changes of -14.88% and -9.08%, respectively.
It is also important to note the recent changes to analyst estimates for Biogen Inc.These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Biogen Inc. currently has a Zacks Rank of #3 (Hold).
Investors should also note Biogen Inc.'s current valuation metrics, including its Forward P/E ratio of 12.33. For comparison, its industry has an average Forward P/E of 21, which means Biogen Inc. is trading at a discount to the group.
We can also see that BIIB currently has a PEG ratio of 0.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.41 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.